AssetMark Inc’s Albany Molecular Research Inc AMRI Stock Holding History

AssetMark Inc’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-16	Closed	–	–	1532
2016 Q4	$0	Buy	+16	New	+$272	﹤0.01%	1453

Other funds holding AMRI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

AssetMark Inc's AMRI Position: Q1 2017 in Review

AssetMark Inc sold out of Albany Molecular Research Inc (AMRI) in Q1 2017, closing a stake of 16 shares.

AssetMark Inc first reported a position in AMRI in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 139 funds tracked by Wall St. Rank hold AMRI as of Q1 2017.

AssetMark Inc reported no remaining Albany Molecular Research Inc position as of Q1 2017 after selling out during the quarter.
AssetMark Inc sold 16 Albany Molecular Research Inc shares in Q1 2017.
AssetMark Inc first reported a position in Albany Molecular Research Inc in Q4 2016 and held it in 1 quarter.
AssetMark Inc's Albany Molecular Research Inc position peaked at $0 in Q4 2016.
139 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2017.

Based on AssetMark Inc's 13F filing for Q1 2017, filed 9 May 2017.